<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1505257393
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BRIVIACT 25MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BRIVARACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        286.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UCB Pharma S.A. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UCB Pharma S.A. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UCB Pharma S.A. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><u>What Briviact is</u></p><p dir="ltr">Briviact contains the active substance brivaracetam. It belongs to a group of medicines called &lsquo;anti‑epileptics&rsquo;. These medicines are used to treat epilepsy.</p><p dir="ltr"><u>What Briviact is used for</u></p><p dir="ltr">Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalisation&rsquo;. Partial seizures are fits that start by only affecting one side of the brain. These partial seizures can spread and extend to larger areas on both sides of the brain &ndash; this is called a &lsquo;secondary generalisation&rsquo;. You have been given this medicine to lower the number of fits (seizures) you have. Briviact is used together with other medicines for epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Briviact if:</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to brivaracetam, other pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section&nbsp;6). If you are not sure, talk to your doctor or pharmacist before taking Briviact.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions </strong></p><p dir="ltr">Talk to your doctor or pharmacist before taking Briviact if:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have thoughts of harming or killing yourself. A small number of people being treated with anti-epileptic medicines such as Briviact have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, contact your doctor immediately.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver problems your doctor may need to adjust your dose.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Children and young people</strong></p><p dir="ltr">Briviact is not recommended for use in children and young people under 16&nbsp;years of age.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Other medicines and Briviact</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p dir="ltr">In particular, your doctor may need to adjust your Briviact dose if you take the following medicines:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin, a medicine used to treat bacterial infections.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s wort, (also known as Hypericum perforatum) a herbal medicine used to treat depression and anxiety and other conditions.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Briviact with alcohol</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Combining this medicine with alcohol is not recommended.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you drink alcohol while taking Briviact the negative effects of alcohol may be increased.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr">It is not recommended to take Briviact if you are pregnant or breast-feeding, as the effects of Briviact on pregnancy and the unborn baby or the new-born child are not known. Seek advice immediately from your doctor if you are pregnant or are planning to become pregnant.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not stop treatment without talking to your doctor first as this could increase your seizures and a worsening of your disease can harm your baby.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may feel sleepy, dizzy or tired while taking Briviact.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These effects are more likely at the start of the treatment or after a dose increase.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not drive, cycle or use any tools or machines until you know how the medicine affects you.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Briviact contains lactose</strong></p><p dir="ltr">Briviact film-coated tablets contain lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">You will take Briviact together with other medicines for epilepsy.</p><p dir="ltr"><u>How much to take</u></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is between 50&nbsp;mg and 200&nbsp;mg each day, your doctor may decide to adjust your optimal dose within the dose range.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the medicine in two equally divided doses <em>-<strong> </strong></em>once in the morning and once in the evening at about the same time each day.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>People with liver problems</u></p><p dir="ltr">If you have problem with your liver, the maximum dose you will take is 150 mg each day.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>How to take Briviact tablets</u></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets<strong><em> </em></strong>whole<strong><em> </em></strong>with a glass of liquid.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicine may be taken with or without food.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>How long to take Briviact for</u></p><p dir="ltr">Briviact is a long term treatment &ndash; keep taking Briviact until your doctor tells you to stop.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you take more Briviact than you should</strong></p><p dir="ltr">If you have taken more Briviact than you should, talk to your doctor. You may feel dizzy and sleepy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to take Briviact</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose take it as soon as you remember.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then take your next dose at the time you would normally take it.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are not sure what to do, ask your doctor or pharmacist</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop taking Briviact</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking this medicine unless your doctor tells you to. This is because stopping treatment could increase the number of fits you have.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor asks you to stop taking this medicine they will lower your dose gradually. This helps to stop your fits coming back or getting worse</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Very common:</strong> may affect more than 1 in 10 people</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy or dizzy.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Common:</strong> may affect up to 1 in 10 people</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired (fatigue)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion, a feeling of &lsquo;spinning&rsquo; (vertigo)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling and being sick, constipation</p><p dir="ltr">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;depression, anxiety, unable to sleep (insomnia), irritability</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections of the nose and throat (such as the &lsquo;common cold&rsquo;), cough</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychotic disorder, being aggressive, thoughts or attempts of harming or killing yourself, nervous excitement (agitation)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in white blood cells (called &lsquo;neutropenia&rsquo;) - shown in blood tests</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Reporting of side effects</strong></p><p dir="ltr">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is brivaracetam.</p><p dir="ltr">Each film-coated tablet contains 10&nbsp;mg, 25&nbsp;mg, 50mg, 75&nbsp;mg, or 100&nbsp;mg brivaracetam.</p><p dir="ltr">The other ingredients are:</p><p dir="ltr"><u>Core</u></p><p dir="ltr">Croscarmellose sodium, lactose monohydrate, betadex, lactose anhydrous, magnesium stearate</p><p dir="ltr"><u>Coating</u></p><p dir="ltr">- 10&nbsp;mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc.</p><p dir="ltr">- 25&nbsp;mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide black (E172).</p><p dir="ltr">- 50&nbsp;mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide red (E172).</p><p dir="ltr">- 75&nbsp;mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172).</p><p dir="ltr">- 100&nbsp;mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Briviact 10 mg are white to off-white, round, film-coated tablets of 6.5 mm in diameter and debossed with ‘u10’ on one side.
Briviact 25 mg are grey, oval, film-coated tablets of 8.9 mm x 5.0 mm and debossed with ‘u25’ on one side.
Briviact 50 mg are yellow, oval, film-coated tablets of 11.7 mm x 6.6 mm and debossed with ‘u50’ on one side.
Briviact 75 mg are purple, oval, film-coated tablets of 13.0 mm x 7.3 mm and debossed with ‘u75’ on one side. 
Briviact 100 mg are green-grey, oval, film-coated tablets of 14.5 mm x 8.1 mm and debossed with ‘u100’ on one side.
	
	Briviact tablets are packaged in blister packs supplied in cardboard boxes containing either 14, 56 or 14 x 1 or 100 x 1 film-coated tablets or in multipacks containing 168 (3 packs of 56) film-coated tablets.All packs are available in PVC/PCTFE - Aluminium blisters.
	
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorisation Holder </strong></p><p dir="ltr">UCB Pharma S.A., All&eacute;e de la Recherche 60, B-1070 Bruxelles, Belgium.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer &amp; Batch Releaser</strong></p><p dir="ltr">UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l&rsquo;Alleud, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><u>ما هو بريفياكت؟</u></p><p dir="RTL">يحتوي بريفياكت على المادة الفعّالة بريفاراسيتام. ينتمي&nbsp; بريفياكت إلى فئة أدوية تُسمى مضادات الصَّرع. تُستَخدَم هذه الأدوية لعلاج الصرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>فيم يُستخدم بريفياكت؟</u></p><p dir="RTL">يُستخدم بريفياكت في البالغين والمراهقين بدءًا من عمر 16 عامًا لعلاج أحد أنواع الصَّرع الذي يتسم بحدوث نوبات تشنجية جزئية مع أو بدون تعميم ثانوي&quot;. النوبات التشنجية الجزئية عبارة عن نوبات تبدأ في الحدوث عن طريق التَّأثير على جانب واحد من المخ فقط. من الممكن أن تنتشر هذه النوبات التشنجية الجزئية وتمتد إلى مناطق أكبر على جانبي المخ -ويسمى ذلك بـ &quot;التَّعميم الثانوي&quot;. تم إعطاؤك هذا الدَّواء لتقليل عدد النوبات (نوبات التشنج) لديك.&nbsp; يُستخدم&nbsp; بريفياكت بمصاحبة أدوية علاج الصرع الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول&nbsp; بريفياكت في الحالات الآتية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه بريفاراسيتام أو أحد مشتقات البيروليدون أو أي مكونات أخرى بهذا الدَّواء (المدرجة في القسم: 6). إذا لم تكن متأكدًا، تحدَّث مع طبيبك أو الصيدلي الخاص بك قبل تناول&nbsp; بريفياكت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول بريفياكت في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا راودتك أفكار لإيذاء نفسك أو قتلها. إذا راود عدد قليل من الأشخاص الذين يتم علاجهم بالأدوية المضادة للصَّرع مثل&nbsp; بريفياكت أفكار لإيذاء أنفسهم أو قتلها. إذا راودك أيٌّ من هذه الأفكار في أي وقت، فاتصل بطبيبك فورًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكبد لديك فقد يحتاج طبيبك إلى تعديل الجرعة الخاصة بك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والشباب</strong></p><p dir="RTL">لا يوصى باستخدام بريفياكت في الأطفال والشباب الذين تقل أعمارهم عن 16 عامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناوُل أدوية أخرى مع بريفياكت</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">على وجه الخصوص، قد يحتاج طبيبك إلى تعديل جرعة&nbsp; بريفياكت الخاصة بك إذا كنت تتناول الأدوية التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، وهو دواء يُستخدم لعلاج العدوى البكتيرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (تعرف أيضًا باسم هايبريكوم برفوراتام) وهو دواء عُشبي يُستخدم لعلاج الاكتئاب والقلق وغيرها من الحالات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول الكحوليات مع بريفياكت </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يوصى بتناول هذا الدَّواء بمصاحبة الكحوليات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولت الكحوليات أثناء تناول&nbsp; بريفياكت، فقد تزداد الآثار السلبية للكحوليات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يوصى بتناول&nbsp; بريفياكت إذا كنتِ حاملًا أو مرضعًا؛ إذ إن تأثيرات&nbsp; بريفياكت على الحمل والجنين أو الطفل حديث الولادة غير معروفة. قومي بطلب المشورة فورًا من طبيبكِ إذا كنتِ حاملًا أو تخططين للحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقومي بوقف العلاج بدون التَّحدث إلى طبيبكِ أولًا؛ إذ قد يزيد هذا من حدوث نوبات التَّشنج لديكِ ومن الممكن أن يؤدي تفاقم المرض لديكِ إلى الإضرار بطفلكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشعر بالنُّعاس أو الدوخة أو التعب أثناء تناول&nbsp; بريفياكت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المرجح حدوث هذه التأثيرات عند بداية العلاج أو بعد زيادة الجرعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تمارس القيادة أو ركوب الدراجات أو استخدام الأدوات أو الآلات حتى تعرف مدى تأثير هذا الدَّواء عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بريفياكت على سكر اللاكتوز</strong></p><p dir="RTL">يحتوي&nbsp; بريفياكت أقراص مغلَّفة على اللاكتوز (نوع من السكر). إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدَّواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستتناول&nbsp; بريفياكت بمصاحبة أدوية علاج الصَّرع الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>ما هي الكمية التي يجب أن تتناولها؟</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح الجرعة الموصى بها بين 50 مجم و200 مجم كل يوم، قد يقرر طبيبك تعديل الجرعة المثلى الخاصة بك في نطاق الجرعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الدَّواء في جرعتين مقسمتين بالتساوي -مرة واحدة في الصباح ومرة واحدة في المساء في الوقت نفسه تقريبًا كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأشخاص المصابون بمشاكل في الكبد</u></p><p dir="RTL">إذا كنت تعاني من مشكلات بالكبد لديك، فستبلغ الجرعة القصوى التي ستتناولها 150 مجم كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>كيف تتناول أقراص بريفياكت؟</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الأقراص كاملة مع كوب من السائل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناوُل هذا الدَّواء مع الطعام أو بدونه.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>المدة التي يجب عليك تناول بريفياكت خلالها</u></p><p dir="RTL">يُعد&nbsp; بريفياكت علاجًا طويل الأمد -استمر في تناول&nbsp; بريفياكت حتى يخبرك طبيبك أن تتوقف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية من بريفياكت أكثر مما يجب</strong></p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من&nbsp; بريفياكت، فتحدَّث إلى طبيبك. قد تشعر بدوخة ونعاس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل بريفياكت</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أغفلت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم تناول جرعتك التَّالية في الوقت المعتاد الذي تتناولها فيه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تكن متأكدًا فاستشر الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول بريفياكت</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتوقَّف عن تناوُل هذا الدَّواء ما لم يُخبرك طبيبك بذلك. هذا لأنَّ التَّوقف عن تناول العلاج قد يزيد من عدد النوبات لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا طلب منك طبيبك أن تتوقف عن تناول هذا الدَّواء فسيقوم بخفض الجرعة الخاصة بك تدريجيًّا. سيُساعد هذا في منع عودة النوبات لديك مرة أخرى أو تفاقمها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًّا:</strong> قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالنعاس أو دوخة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة:</strong> قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزلة برد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتعب شديد (إرهاق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلاج، شعور بالدوران (الدوار).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء والإعياء، الإمساك.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp;&nbsp; اكتئاب، قلق، عدم القدرة على النوم (أَرَق)، هياج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالأنف والحلق (مثل: &quot;نزلة برد&quot;)، وسعال.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; انخفاض الشهية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة: </strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100&nbsp;أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ذهاني، التَّصرف بعدوانية، أفكار أو محاولات لإيذاء نفسك أو قتلها، إثارة عصبية (هِياج).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خلايا الدَّم البيضاء (يدعى &quot;قلة خلايا العَدِلات&quot;) - تم ظهورها في اختبارات الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا ظهرت لديك أية آثار جانبية، تحدَّث إلى الطبيب أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة؛ غير المُدرجة في هذه النَّشرة.من خلال إبلاغك عن الآثار الجانبية، يُمكِنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>&nbsp;يُحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بريفاراسيتام.</p><p dir="RTL">يحتوي كل قرص مغلف على 10&nbsp;مجم، أو 25&nbsp;مجم، أو 50&nbsp;مجم بريفاراسيتام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><u>محتوى القرص الداخلي</u></p><p dir="RTL">كروسكارميلوز الصوديوم، لاكتوز أحادي الهيدرات، بيتادكس، لاكتوز لا مائي، ستيرات الماغنسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>طبقة الغلاف</u></p><p dir="RTL">- أقراص مغلَّفة 10 مجم: كحول عديد الفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك.</p><p dir="RTL">- أقراص مغلَّفة 25 مجم: كحول عديد الفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأسود(E172 ) .</p><p dir="RTL">- أقراص مغلفة 50 مجم: كحول عديد الفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأحمر (E172 ).</p><p dir="RTL">-&nbsp; أقراص مغلَّفة 75 مجم: كحول عديد الفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأحمر (E172 )، أكسيد الحديد الأسود (E172).</p><p dir="RTL">-&nbsp; أقراص مُغلَّفة 100 مجم: كحول عديد الفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأسود (E172) .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;بريفياكت 10 مجم عبارة عن أقراص مغلَّفة ذات لون أبيض يميل إلى الاصفرار، دائرية الشكل ويبلغ قطرها 6.5 مللي متر ومحفور على أحد جانبيها &quot;u10&quot;.</p><p dir="RTL">&nbsp;بريفياكت 25 مجم عبارة عن أقراص مغلَّفة ذات لون رمادي، بيضاوية الشكل ويبلغ قطرها 8.9 مللي متر&times; 5.0 مللي متر&nbsp;ومحفور على أحد جانبيها &quot;u25&quot;.</p><p dir="RTL">&nbsp;بريفياكت 50 مجم عبارة عن أقراص مغلَّفة ذات لون أصفر، بيضاوية الشكل ويبلغ قطرها &nbsp;11.7 مللي متر&times; 6.6 مللي متر&nbsp;ومحفور على أحد جانبيها &quot;u50&quot;.</p><p dir="RTL">&nbsp;بريفياكت 75 مجم عبارة عن أقراص مغلَّفة ذات لون أرجواني، بيضاوية الشكل ويبلغ قطرها &nbsp;13.0 مللي متر&times; 7.3 مللي متر&nbsp;ومحفور على أحد جانبيها &quot;u75&quot;.</p><p dir="RTL">&nbsp;بريفياكت 100 مجم عبارة عن أقراص مغلَّفة ذات لون أخضر- رمادي، بيضاوية الشكل ويبلغ قطرها &nbsp;14.5 مللي متر&times; 8.1 مللي متر&nbsp;ومحفور على أحد جانبيها &quot;u100&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتم تعبئة أقراص&nbsp; بريفياكت في عبوات بها أشرطة تتوفر في عبوات كرتونية تحتوي على إما 14 &nbsp;أو 56 أو 14 &times; 1 أو 100 &times; 1 أقراص مغلَّفة أو في عبوات متعددة تحتوي على 168 (3 عبوات بها 56) قرصًا مغلفًا.</p><p dir="RTL">تتوفر جميع العبوات في أشرطة من بولي فينيل الكلوريد/ عديد كلورو ثلاثي فلورو الإثيلين - الألومنيوم.</p><p dir="RTL">&nbsp;</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق </strong></p><p>UCB Pharma S.A., All&eacute;e de la Recherche 60, B-1070 Bruxelles, Belgium.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p>UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l&rsquo;Alleud, Belgium</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2017/04
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Briviact 10 mg film-coated tablets
Briviact 25 mg film-coated tablets
Briviact 50 mg film-coated tablets
Briviact 75 mg film-coated tablets
Briviact 100 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Briviact 10 mg film-coated tablets
Each film-coated tablet contains 10 mg brivaracetam.

Briviact 25 mg film-coated tablets
Each film-coated tablet contains 25 mg brivaracetam.

Briviact 50 mg film-coated tablets
Each film-coated tablet contains 50 mg brivaracetam.

Briviact 75 mg film-coated tablets
Each film-coated tablet contains 75 mg brivaracetam.

Briviact 100 mg film-coated tablets
Each film-coated tablet contains 100 mg brivaracetam.

Excipient(s) with known effect:

Briviact 10 mg film-coated tablets
Each 10 mg film-coated tablet contains 88 mg lactose.

Briviact 25 mg film-coated tablets
Each 25 mg film-coated tablet contains 94 mg lactose. 

Briviact 50 mg film-coated tablets
Each 50 mg film-coated tablet contains 189 mg lactose. 

Briviact 75 mg film-coated tablets
Each 75 mg film-coated tablet contains 283 mg lactose. 

Briviact 100 mg film-coated tablets
Each 100 mg film-coated tablet contains 377 mg lactose.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablets)

Briviact 10 mg film-coated tablets
White to off-white, round film-coated tablets of 6.5 mm in diameter and debossed with ‘u10’ on one side.

Briviact 25 mg film-coated tablets
Grey, oval film-coated tablets with dimensions of 8.9 mm x 5.0 mm and debossed with ‘u25’ on one side.

Briviact 50 mg film-coated tablets
Yellow, oval film-coated tablets with dimensions of 11.7 mm x 6.6 mm and debossed with ‘u50’ on one side.

Briviact 75 mg film-coated tablets
Purple, oval film-coated tablets with dimensions of 13.0 mm x 7.3 mm debossed with ‘u75’ on one side. 
Briviact 100 mg film-coated tablets

Green-grey, oval film-coated tablets with dimensions of 14.5 mm x 8.1 mm and debossed with ‘u100’ on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Posology</u></p><p dir="ltr">The recommended starting dose is either 50&nbsp;mg/day or 100&nbsp;mg/day based on physician assessment of required seizure reduction versus potential side effects. The dose should be administered in two equally divided doses, once in the morning and once in the evening. Based on individual patient response and tolerability, the dose may be adjusted in the dose range of 50&nbsp;mg/day to 200&nbsp;mg/day.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Missed doses</em></p><p dir="ltr">If patients missed one dose or more, it is recommended that they take a single dose as soon as they remember and take the following dose at the usual morning or evening time. This may avoid the brivaracetam plasma concentration falling below the efficacy level and prevent breakthrough seizures from occurring.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Discontinuation</em></p><p dir="ltr">If brivaracetam has to be discontinued it is recommended to withdraw it gradually by 50&nbsp;mg/day on a weekly basis. After 1 week of treatment at 50&nbsp;mg/day, a final week of treatment at the dose of 20&nbsp;mg/day is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr"><em>Elderly (65 years of age and above)</em></p><p dir="ltr">No dose adjustment is needed in elderly patients (see section 5.2).</p><p dir="ltr">The clinical experience in patients &ge; 65 years is limited.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">No dose adjustment is needed in patients with impaired renal function (see section 5.2). Brivaracetam is not recommended in end-stage renal disease patients undergoing dialysis due to lack of data.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr">Exposure to brivaracetam was increased in patients with chronic liver disease. A 50&nbsp;mg/day starting dose should be considered. A maximum daily dose of 150&nbsp;mg administered in 2 divided doses is recommended for all stages of hepatic impairment (see section 4.4 and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">The safety and efficacy of brivaracetam in children aged less than 16<strong><em> </em></strong>years have not yet been established.</p><p dir="ltr">Currently available data are described in section 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.</p><p dir="ltr"><strong><em>&nbsp;</em></strong></p><p dir="ltr"><u>Method of administration </u></p><p dir="ltr">Brivaracetam film-coated tablets must be taken orally swallowed in whole with liquid and may be taken with or without food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Suicidal ideation and behaviour</u></p><p dir="ltr">Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic drugs (AEDs), including brivaracetam, in several indications. A meta-analysis of randomized placebo-controlled trials of AEDs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for brivaracetam.</p><p dir="ltr">Patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should any signs of suicidal ideation or behaviour emerge.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Hepatic impairment</u></p><p dir="ltr">There are limited clinical data on the use of brivaracetam in patients with pre-existing hepatic impairment. Dose adjustments are recommended for patients with hepatic impairment (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Lactose intolerance</u></p><p dir="ltr">Brivaracetam film-coated tablets contain lactose. Patients with rare heriditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Formal interaction studies have only been performed in adults.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacodynamic interactions</u></p><p dir="ltr"><em>Concomitant treatment with levetiracetam</em></p><p dir="ltr">In the clinical studies,<strong><em> </em></strong>although the numbers were limited,<strong><em> </em></strong>there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently. No additional safety or tolerability concern was observed (see section 5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Interaction with alcohol</em></p><p dir="ltr">In a pharmacokinetic and pharmacodynamic interaction study between brivaracetam 200&nbsp;mg single dose and ethanol 0.6&nbsp;g/L continuous infusion in healthy subjects, there was no pharmacokinetic interaction but brivaracetam approximately doubled the effect of alcohol on psychomotor function, attention and memory. Intake of brivaracetam with alcohol is not recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacokinetic interactions</u></p><p dir="ltr"><em>Effects of other </em><em>agents on the pharmacokinetics of </em><em>brivaracetam</em></p><p dir="ltr"><em>In vitro</em> data suggest that brivaracetam has a low interaction potential. The main disposition pathway of brivaracetam is by CYP-independent hydrolysis. A second disposition pathway involves hydroxylation mediated by CYP2C19 (see section 5.2).</p><p dir="ltr">Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluconazole, fluvoxamine), but the risk of a clinically relevant CYP2C19‑mediated interaction is considered to be low.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Rifampicin</em></p><p dir="ltr">In healthy subjects, coadministration with the strong enzyme inducer<strong><em> </em></strong>rifampicin (600&nbsp;mg/day for 5&nbsp;days), decreased brivaracetam area under the plasma concentration curve (AUC) by 45&nbsp;%.&nbsp;Prescribers should consider adjusting the brivaracetam dose in patients starting or ending treatment with rifampicin.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Strong enzyme inducing AEDs</em></p><p dir="ltr">Brivaracetam plasma concentrations are decreased when coadministered with strong enzyme inducing AEDs (carbamazepine, phenobarbital, phenytoin) but no dose adjustment is required (see table 1).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Other </em><em>enzyme inducers</em></p><p dir="ltr">Other strong enzyme inducers (such as St John&acute;s wort (Hypericum perforatum)) may also decrease the systemic exposure of brivaracetam. Therefore, starting or ending treatment with St John&rsquo;s wort should be done with caution.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Effects of brivaracetam on other medicinal products</em></p><p dir="ltr">Brivaracetam given 50 or 150&nbsp;mg/day did not affect the AUC of midazolam (metabolised by CYP3A4). The risk of clinically relevant CYP3A4 interactions is considered to be low.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>In vitro </em>studies have shown that brivaracetam exhibits little or no inhibition of CYP450 isoforms except for CYP2C19. Brivaracetam may increase plasma concentrations of medicinal products metabolised by CYP2C19 (e.g. lanzoprazole, omeprazole, diazepam). When tested <em>in vitro</em> brivaracetam did not induce CYP1A1/2 but induced CYP3A4 and CYP2B6. No CYP3A4 induction was found <em>in vivo</em> (see midazolam above). CYP2B6 induction has not been investigated <em>in vivo</em> and brivaracetam may decrease plasma concentrations of medicinal products metabolised by CYP2B6 (e.g. efavirenz). In vitro interaction studies to determine the potential inhibitory effects on transporters concluded that there were no clinically relevant effects, except for OAT3. <em>In vitro</em>, Brivaracetam inhibits OAT3 with a half maximal inhibitory concentration 42-fold higher than the C<sub>max</sub> at the highest clinical dose. Brivaracetam 200mg/day may increase plasma concentrations of medicinal products transported by OAT3.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Antiepileptic drugs</u></p><p dir="ltr">Potential interactions between brivaracetam (50&nbsp;mg/day to 200&nbsp;mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies, in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug-drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate). The effect of the interactions on the plasma concentration is summarised in table 1 (increase is indicated as &ldquo;&uarr;&rdquo; and decrease as &ldquo;&darr;&rdquo;, area under the plasma concentration versus time curve as &ldquo;AUC&rdquo;, maximum observed concentration as C<sub>max</sub>).</p><p dir="ltr">Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:618px"><tbody><tr><td style="vertical-align:top"><p><strong>AED coadministered</strong></p></td><td style="vertical-align:top"><p><strong>Influence of AED on brivaracetam plasma concentration</strong></p></td><td style="vertical-align:top"><p><strong>Influence of brivaracetam on AED plasma concentration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>AUC 29&nbsp;% &darr;</p><p>C<sub>max </sub>13&nbsp;% &darr;</p><p>No dose adjustment required</p></td><td style="vertical-align:top"><p>Carbamazepine - None</p><p>Carbamazepine-epoxide &uarr;</p><p>(See below)<br />No dose adjustment required.</p></td></tr><tr><td style="vertical-align:top"><p>Clobazam</p></td><td style="vertical-align:top"><p>No data available</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Clonazepam</p></td><td style="vertical-align:top"><p>No data available</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Lacosamide</p></td><td style="vertical-align:top"><p>No data available</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Lamotrigine</p></td><td style="vertical-align:top"><p>None</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Levetiracetam</p></td><td style="vertical-align:top"><p>None</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Oxcarbazepine</p></td><td style="vertical-align:top"><p>None</p></td><td style="vertical-align:top"><p>None (monohydroxy derivative, MHD)</p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital</p></td><td style="vertical-align:top"><p>AUC 19&nbsp;% &darr;</p><p>No dose adjustment required</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>AUC 21&nbsp;% &darr;</p><p>No dose adjustment required</p></td><td style="vertical-align:top"><p>None</p><p><sup>a</sup> AUC 20% &uarr;</p><p><sup>a</sup> C<sub>max</sub> 20% &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Pregabalin</p></td><td style="vertical-align:top"><p>No data available</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Topiramate</p></td><td style="vertical-align:top"><p>None</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Valproic acid</p></td><td style="vertical-align:top"><p>None</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Zonisamide</p></td><td style="vertical-align:top"><p>No data available</p></td><td style="vertical-align:top"><p>None</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup> based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Carbamazepine </em></p><p dir="ltr">Brivaracetam is a moderate reversible inhibitor of epoxide hydrolase resulting in an increased concentration of carbamazepine epoxide, an active metabolite of carbamazepine. In controlled studies, the carbamazepine epoxide plasma concentration increased by a mean of 37&nbsp;%, 62&nbsp;% and 98&nbsp;% with little variability at brivaracetam doses of 50&nbsp;mg/day, 100&nbsp;mg/day and 200&nbsp;mg/day respectively. No safety risks were observed. There was no additive effect of brivaracetam and valproate on the AUC of carbamazepine epoxide.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Oral contraceptives</u></p><p dir="ltr">Co-administration of brivaracetam (100&nbsp;mg/day) with an oral contraceptive containing ethinylestradiol (0.03&nbsp;mg) and levonorgestrel (0.15&nbsp;mg) did not influence the pharmacokinetics of either substance. When brivaracetam was coadministered at a dose of 400&nbsp;mg/day (twice the recommended maximum daily dose) with an oral contraceptive containing ethinylestradiol (0.03&nbsp;mg) and levonorgestrel (0.15&nbsp;mg), a reduction in estrogen and progestin AUCs of 27&nbsp;% and 23&nbsp;%, respectively, was observed without impact on suppression of ovulation. There was generally no change in the concentration-time profiles of the endogenous markers estradiol, progesterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), and sex hormone binding globulin (SHBG).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Women of childbearing potential </u></p><p dir="ltr">Physicians should discuss family planning and contraception with women of childbearing potential taking brivaracetam (see Pregnancy).</p><p dir="ltr">If a woman decides to become pregnant, the use of brivaracetam should be carefully re-evaluated.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pregnancy</u></p><p dir="ltr"><em>Risk related to epilepsy and antiepileptic medicinal products in general</em></p><p dir="ltr">For all anti-epileptic drugs, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3&nbsp;% in the general population. In the treated population, an increase in malformations has been noted with polytherapy; however, the extent to which the treatment and/or the underlying condition is responsible has not been elucidated. Discontinuation of anti-epileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Risk related to brivaracetam</em></p><p dir="ltr">There is a limited amount of data from the use of brivaracetam in pregnant women. There is no data on placental transfer in humans, but brivaracetam was shown to readily cross the placenta in rats (see section 5.3). The potential risk for humans is unknown. Animal studies did not detect any teratogenic potential of brivaracetam (see section 5.3).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In clinical studies, brivaracetam was used as adjunctive therapy and when it was used with carbamazepine, it induced a dose-related increase in the concentration of the active metabolite, carbamazepine-epoxide (see section 4.5). There is insufficient data to determine the clinical significance of this effect in pregnancy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">As a precautionary measure, brivaracetam should not be used during pregnancy unless clinically necessary i.e. (if the benefit to the mother clearly outweighs the potential risk to the foetus).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">It is unknown whether brivaracetam is excreted in human breast milk. Studies in rats have shown excretion of brivaracetam in breast milk (see section 5.3). A decision should be made whether to discontinue breastfeeding or to discontinue brivaracetam, taking into account the benefit of the medicinal product to the mother. In case of co-administration of brivaracetam and carbamazepine, the amount of carbamazepine-epoxide excreted in breast milk could increase. There is insufficient data to determine the clinical significance.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">No human data on the effect of brivaracetam on fertility are available. In rats, there was no effect on fertility with brivaracetam (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Brivaracetam has minor or moderate influence on the ability to drive and use machines.</p><p dir="ltr">Due to possible differences in individual sensitivity some patients might experience somnolence, dizziness, and other central nervous system (CNS) related symptoms. Patients should be advised not to drive a car or to operate other potentially hazardous machines until they are familiar with the effects of brivaracetam on their ability to perform such activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">In all controlled and uncontrolled trials in patients with epilepsy, 2,388 subjects have received brivaracetam, of whom 1,740 have been treated for &ge; 6 months,1,363 for &ge; 12 months, 923 for &ge;24 months and 569 for &ge; 60 months (5 years).</p><p dir="ltr">The most frequently reported adverse reactions (&gt;10&nbsp;%) with brivaracetam treatment were: somnolence (14.3&nbsp;%) and dizziness (11.0&nbsp;%). They were usually mild to moderate in intensity. Somnolence and fatigue (8.2&nbsp;%) were reported at a higher incidence with increasing dose. The types of adverse reactions reported during the first 7 days of treatment were similar to those reported for the overall treatment period.</p><p dir="ltr">The discontinuation rate due to adverse reactions was 3.5&nbsp;%, 3.4&nbsp;% and 4.0&nbsp;% for patients randomized to brivaracetam at respectively the dose of 50&nbsp;mg/day, 100&nbsp;mg/day and 200&nbsp;mg/day and 1.7&nbsp;% for patients randomized to placebo. The adverse reactions most frequently resulting in discontinuation of brivaracetam therapy were dizziness (0.8&nbsp;%) and convulsion (0.8&nbsp;%).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">In the table below, adverse reactions, which were identified based on review of the full brivaracetam clinical studies safety database, are listed by System Organ Class and frequency.</p><p dir="ltr">The frequencies are defined as follows: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions from clinical trials</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Influenza</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Type I hypersensitivity</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Depression, anxiety, insomnia, irritability</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Suicidal ideation, psychotic disorder, aggression, agitation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dizziness, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Common<br />&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion, vertigo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Common<br />&nbsp;</p></td><td style="vertical-align:top"><p>Upper respiratory tract infections, cough</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Common<br />&nbsp;</p></td><td style="vertical-align:top"><p>Nausea, vomiting, constipation</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Common<br />&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr">Neutropenia has been reported in 0.5&nbsp;% (6/1099) brivaracetam patients and 0&nbsp;% (0/459) placebo patients. Four of these subjects had decreased neutrophil counts at baseline, and experienced additional decrease in neutrophil counts after initiation of brivaracetam treatment. None of the 6 cases of neutropenia were severe, required any specific treatment or led to discontinuation of brivaracetam and none had associated infections.</p><p dir="ltr">Suicidal ideation has been reported in 0.3&nbsp;% (3/1099) brivaracetam patients and 0.7&nbsp;% (3/459) placebo patients. In the short-term clinical studies of brivaracetam in epilepsy patients, there were no cases of completed suicide and suicide attempt, however both have been reported in open-label extension studies (see section 4.4).</p><p dir="ltr">Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of brivaracetam patients (9/3022) during clinical development.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Open-label extension studies</u></p><p dir="ltr">In patients who were followed up in the open-label extension studies for up to 8 years, the safety profile was similar to that observed in the short-term, placebo-controlled studies.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">There are limited safety data from open-label studies in children from 1 month to &lt; 16 years of age. A total of 152 children (1 month to &lt; 16 years of age) were treated with brivaracetam in a pharmacokinetic study and the related follow up study. From the limited available data, the most frequently reported TEAEs considered drug-related by the investigator were somnolence (10&nbsp;%), decreased appetite (8&nbsp;%), fatigue (5&nbsp;%) and weight decreased (5&nbsp;%).The safety profile appears to be consistent with that known in adults. No data are available on neurodevelopment. Currently, no clinical data are available in neonates.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elderly </u></p><p dir="ltr">Of the 130 elderly subjects enrolled in the brivaracetam phase 2/3 development program (44 with epilepsy), 100 were 65-74 years of age and 30 were 75-84 years of age. The safety profile in elderly patients appears to be similar to that observed in younger adult patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Reporting of suspected adverse reactions</u></p><p dir="ltr">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below:</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li>&nbsp;&nbsp;<strong><em>Saudi Arabia:</em></strong></li></ul><p dir="ltr">-&nbsp; &nbsp;The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p dir="ltr">o Fax: +966-11-205-7662</p><p dir="ltr">o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p dir="ltr">o Toll free phone: 8002490000</p><p dir="ltr">o E-mail: npc.drug@sfda.gov.sa</p><p dir="ltr">o Website: www.sfda.gov.sa/npc</p><ul dir="ltr"><li>&nbsp;<strong><em>Other GCC States:</em></strong></li></ul><p dir="ltr">-&nbsp; &nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Symptoms</u></p><p dir="ltr">There is limited clinical experience with brivaracetam overdose in humans. Somnolence and dizziness have been reported in a healthy subject taking a single dose of 1,400&nbsp;mg of brivaracetam.</p><p dir="ltr"><u>Management of overdose</u></p><p dir="ltr">There is no specific antidote for overdose with brivaracetam. Treatment of an overdose should include general supportive measures. Since less than 10&nbsp;% of brivaracetam is excreted in urine, haemodialysis is not expected to significantly enhance brivaracetam clearance (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX23</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein found at presynaptic level in neurons and in endocrine cells. Although the exact role of this protein remains to be elucidated it has been shown to modulate exocytosis of neurotransmitters. Binding to SV2A is believed to be the primary mechanism for brivaracetam anticonvulsant activity.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical efficacy and safety</u></p><p dir="ltr">The efficacy of brivaracetam for the adjunctive therapy of partial-onset seizures (POS) was established in 3 randomized, double-blind, placebo-controlled, fixed-dose, multi-center studies in subjects 16&nbsp;years of age and older. The daily dose of brivaracetam ranged from 5 to 200&nbsp;mg/day across these studies. All studies had an 8-week baseline period followed by a 12-week treatment period with no up-titration. 1,558 patients received study drug of which 1,099 received brivaracetam. Study enrollment criteria required that patients have uncontrolled POS despite treatment with either 1 or 2 concomitant AEDs. Patients were required to have at least 8 POS during the baseline period. The primary endpoints in the phase 3 studies were the percent reduction in POS frequency over placebo and the 50&nbsp;% responder rate based on 50&nbsp;% reduction in POS frequency from baseline.</p><p dir="ltr">The most commonly taken AEDs at the time of study entry were carbamazepine (40.6&nbsp;%), lamotrigine (25.2&nbsp;%), valproate (20.5&nbsp;%), oxcarbazepine (16.0&nbsp;%), topiramate (13.5&nbsp;%), phenytoin (10.2&nbsp;%) and levetiracetam (9.8&nbsp;%). The median baseline seizure frequency across the 3 studies was 9 seizures per 28 days. Patients had a mean duration of epilepsy of approximately 23 years.</p><p dir="ltr">The efficacy outcomes are summarized in Table 2. Overall, brivaracetam was efficacious for the adjunctive treatment of partial onset seizures in patients 16 years of age and older between 50&nbsp;mg/day and 200&nbsp;mg/day.</p><p dir="ltr"><em>Table 2: Key Efficacy Outcomes for Partial Onset Seizure Frequency per 28 Days</em></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:619px"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Study</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Brivaracetam </strong></p><p><sup>* Statistically significant<strong> (p-value)</strong></sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>50</strong>&nbsp;<strong>mg/day</strong></p></td><td style="vertical-align:top"><p><strong>100</strong>&nbsp;<strong>mg/day</strong></p></td><td style="vertical-align:top"><p><strong>200</strong>&nbsp;<strong>mg/day</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Study N01253</strong><sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n= 96</p></td><td style="vertical-align:top"><p>n= 101</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>50&nbsp;% Responder rate</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>32.7<sup>* </sup></p><p><sup>(p=0.008)</sup></p></td><td style="vertical-align:top"><p>~</p></td><td style="vertical-align:top"><p>~</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent reduction over placebo (%)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>22.0<sup>* </sup></p><p><sup>(p=0.0040)</sup></p></td><td style="vertical-align:top"><p>~</p></td><td style="vertical-align:top"><p>~</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Study N01252</strong><sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n = 100</p></td><td style="vertical-align:top"><p>n = 99</p></td><td style="vertical-align:top"><p>n = 100</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>50 % Responder rate</p></td><td style="vertical-align:top"><p>20.0</p></td><td style="vertical-align:top"><p>27.3</p><p><sup>(p=0.372)</sup></p></td><td style="vertical-align:top"><p>36.0<sup>(2) (p=0.023)</sup></p></td><td style="vertical-align:top"><p>~</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent reduction over placebo (%)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>9.2</p><p><sup>(p=0.0274)</sup></p></td><td style="vertical-align:top"><p>20.5<sup>(2) (p=0.0097)</sup></p></td><td style="vertical-align:top"><p>~</p><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Study N01358</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n = 259</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n = 252</p></td><td style="vertical-align:top"><p>n = 249</p></td></tr><tr><td style="vertical-align:top"><p>50% Responder rate</p></td><td style="vertical-align:top"><p>21.6</p></td><td style="vertical-align:top"><p>~</p></td><td style="vertical-align:top"><p>38.9</p><p><sup>(p&lt;0.001)</sup></p></td><td style="vertical-align:top"><p>37.8</p><p><sup>(p&lt;0.001)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Percent reduction over placebo (%)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>~</p></td><td style="vertical-align:top"><p>22.8<sup>* </sup></p><p><sup>(p&lt;0.001) </sup></p></td><td style="vertical-align:top"><p>23.2<sup>* </sup></p><p><sup>(p&lt;0.001)</sup></p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">n = randomised patients who received at least 1 dose of study medication<sup> </sup></p><p dir="ltr">~ Dose not studied</p><p dir="ltr"><sup>*</sup> Statistically significant</p><p dir="ltr"><sup>(1)</sup> Approximately 20&nbsp;% of the patients were on concomitant levetiracetam</p><p dir="ltr"><sup>(2)</sup> The primary outcome for N01252 did not achieve statistical significance based on the sequential testing procedure. The 100&nbsp;mg/day dose was nominally significant.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In clinical studies, a reduction in seizure frequency over placebo was higher with the dose of 100&nbsp;mg/day than with 50&nbsp;mg/day. Apart from dose-dependent increases in incidences of somnolence and fatigue brivaracetam 50&nbsp;mg/day and 100&nbsp;mg/day had a similar safety profile including CNS-related AEs and with long-term use.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 1 shows the percentage of patients (excluding patients with concomitant levetiracetam) by category of reduction from baseline in POS frequency per 28 days in all 3 studies. Patients with more than a 25&nbsp;% increase in POS are shown at left as &ldquo;worse&rdquo;. Patients with an improvement in percent reduction in baseline POS frequency are shown in the 4 right-most categories. The percentages of patients with at least a 50&nbsp;% reduction in seizure frequency were 20.3&nbsp;%, 34.2&nbsp;%, 39.5&nbsp;%, and 37.8&nbsp;% for placebo, 50&nbsp;mg/day, 100&nbsp;mg/day, and 200&nbsp;mg/day, respectively. &nbsp;</p><p><em>Figure 1:&nbsp;&nbsp;&nbsp; Proportion of patients by category of seizure response for brivaracetam and placebo over 12 weeks across all three double-blind pivotal trials</em></p><p><em><img alt="" width="807" height="517" src="data:image/png;base64,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" /></em></p><p>&nbsp;</p><p dir="ltr">In a pooled analysis of the three pivotal trials, no differences in efficacy&nbsp;(measured as 50&nbsp;% responder rate) was observed within the dose range of&nbsp;50&nbsp;mg/day to 200&nbsp;mg/day when brivaracetam is combined with inducing or non-inducing AEDs. In clinical studies 2.5&nbsp;% (4/161), 5.1&nbsp;% (17/332) and 4.0% (10/249) of the patients on brivaracetam 50&nbsp;mg/day, 100&nbsp;mg/day and 200&nbsp;mg/day respectively became seizure free during the 12-week treatment period compared with 0.5&nbsp;% (2/418) on placebo.</p><p dir="ltr">Improvement in the median percent reduction in seizure frequency per 28 days has been observed in patients with type IC seizure (secondary generalized tonic-clonic seizures) at baseline treated with brivaracetam (66.6&nbsp;% (n=62), 61.2&nbsp;% (n=100) and 82.1&nbsp;% (n=75) of the patients on brivaracetam 50&nbsp;mg/day, 100&nbsp;mg/day and 200&nbsp;mg/day respectively as compared to placebo 33.3&nbsp;% (n=115)).</p><p dir="ltr">The efficacy of brivaracetam in monotherapy has not been established. Brivaracetam is not recommended for use in monotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Treatment with levetiracetam</u></p><p dir="ltr">In two phase 3 randomised placebo-controlled studies, levetiracetam was administered as concomitant AED in about 20&nbsp;% of the patients. Although the number of subjects is limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently which may reflect competition at the SV2A binding site. No additional safety or tolerability concerns were observed.</p><p dir="ltr">In a third study, a pre-specified analysis demonstrated efficacy over placebo for 100 mg/day and 200&nbsp;mg/day in patients with prior exposure to levetiracetam. The lower efficacy observed in these patients compared to the leveticacetam-na&iuml;ve patients was likely due to the higher number of prior AEDs used and higher baseline seizure frequency.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Elderly (65 years of age and above)</em></p><p dir="ltr">The three pivotal double-blind placebo-controlled studies included 38 elderly patients aged between 65 and 80 years. Although data are limited, the efficacy was comparable to younger subjects.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Open label extension studies</em></p><p dir="ltr">Across all studies, 81.7&nbsp;% of the patients who completed randomized studies were enrolled in the long-term open-label extension studies. From entry into the randomized studies,5.3&nbsp;% of the subjects exposed to brivaracetam for 6&nbsp;months (n=1,500) were seizure free compared to 4.6&nbsp;% and 3.7&nbsp;% for subjects exposed for 12&nbsp;months (n=1,188) and 24 months (n=847), respectively. However, as a high proportion of subjects (26%) discontinued from the open-label studies due to lack of efficacy, a selection bias may have occurred, as the subjects who stayed in the study responded better than those who have terminated prematurely.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">The efficacy and tolerability of brivaracetam in paediatric patients have not been established (see section 4.2). Brivaracetam was evaluated in these patients in short term open label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).</p><p dir="ltr">The European Medicines Agency has deferred the obligation to submit the results of studies with brivaracetam in one or more subsets of the paediatric population in epilepsy with partial onset seizures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Brivaracetam film-coated tablets, oral solution and solution for intravenous injection show the same AUC, while the maximum plasma concentration is slightly higher after intravenous administration. Brivaracetam exhibits linear and time-independent pharmacokinetics with low intra- and inter-subject variability, and features complete absorption, very low protein binding, renal excretion following extensive biotransformation, and pharmacologically inactive metabolites.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Absorption</u></p><p dir="ltr">Brivaracetam is rapidly and completely absorbed after oral administration and the absolute bioavailablity is approximately 100&nbsp;%. The median t<sub>max</sub> for tablets taken without food is 1 hour (t<sub>max</sub> range is 0.25 to 3&nbsp;h).</p><p dir="ltr">Coadministration with a high-fat meal slowed down the absorption rate (median t<sub>max</sub> 3&nbsp;h) and decreased the maximum plasma concentration (37&nbsp;% lower) of brivaracetam, while the extent of absorption remained unchanged.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">Brivaracetam is weakly bound (&le; 20&nbsp;%) to plasma proteins. The volume of distribution is 0.5&nbsp;L/kg, a value close to that of the total body water.</p><p dir="ltr">Due to its lipophylicity (Log P) brivaracetam has high cell membrane permeability.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr">Brivaracetam is primarily metabolized by hydrolysis of the amide moiety to form the corresponding carboxylic acid (approximately 60&nbsp;% the elimination), and secondarily by hydroxylation on the propyl side chain (approximately 30&nbsp;% the elimination). The hydrolysis of the amide moiety leading to the carboxylic acid metabolite (34&nbsp;% of the dose in urine) is supported by hepatic and extra-hepatic amidase. <em>In vitro</em>, the hydroxylation of brivaracetam is mediated primarily by CYP2C19. Both metabolites, are further metabolised forming a common hydroxylated acid formed predominantly by hydroxylation of the propyl side chain on the carboxylic acid metabolite (mainly by CYP2C9).<em> In vivo</em>, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 10-fold while brivaracetam itself is increased by 22&nbsp;% or 42&nbsp;% in individuals with one or both mutated alleles. The three metabolites are not pharmacologically active.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">Brivaracetam is eliminated primarily by metabolism and by excretion in the urine. More than 95&nbsp;% of the dose, including metabolites, is excreted in the urine within 72&nbsp;hours after intake. Less than 1&nbsp;% of the dose is excreted in faeces and less than 10&nbsp;% of brivaracetam is excreted unchanged in urine. The terminal plasma half-life (t1/2) is approximately 9&nbsp;hours.<strong><em> </em></strong>The total plasma clearance in patients was estimated to 3.6 L/h.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Linearity</u></p><p dir="ltr">Pharmacokinetics is dose-proportional from 10 to at least 600&nbsp;mg.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Interactions </u><u>with medicinal products</u></p><p dir="ltr">Brivaracetam is cleared by multiple pathways including renal excretion, non-CYP-mediated hydrolysis and CYP-mediated oxidations. <em>In vitro</em>, brivaracetam is not a substrate of human P-glycoprotein (P-gp), multidrug resistance proteins (MRP) 1 and 2, and likely not organic anion transporter polypeptide 1B1 (OATP1B1) and OATP1B3.</p><p dir="ltr"><em>In vitro</em> assays showed that brivaracetam disposition should not be significantly affected by CYP (eg. CYP1A, 2C8, 2C9, 2D6 and 3A4) inhibitors.</p><p dir="ltr">In vitro, brivaracetam was not an inhibitor of the CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4, or the transporters P-gp, BCRP, BSEP MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 and OCT1 at clinically relevant concentrations. In vitro, brivaracetam did ot induce CYP1A2.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacokinetics in special patient groups</u></p><p dir="ltr"><em>Elderly </em><em>(65 years of age and above)</em></p><p dir="ltr">In a study in elderly subjects (65 to79 years old; with creatinine clearance 53 to 98&nbsp;ml/min/1.73 m&sup2;) receiving brivaracetam 400&nbsp;mg/day in bid administration, the plasma half-life of brivaracetam was 7.9&nbsp;hours and 9.3&nbsp;hours in the 65 to 75 and &gt;75&nbsp;years groups, respectively. The steady-state plasma clearance of brivaracetam was similar (0.76&nbsp;ml/min/kg) to young healthy male subjects (0.83&nbsp;ml/min/kg) (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">A study in subjects with severe renal impairment (creatinine clearance &lt;30&nbsp;ml/min/1.73&nbsp;m&sup2; and not requiring dialysis) revealed that the plasma AUC of brivaracetam was moderately increased (+21&nbsp;%) relative to healthy controls, while the AUC of the acid, hydroxy and hydroxyacid metabolites were increased 3-, 4-, and 21-fold, respectively. The renal clearance of these non active metabolites was decreased 10-fold. The hydroxyacid metabolite did not reveal any safety concerns in non clinical studies. Brivaracetam has not been studied in patients undergoing hemodialysis (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr">A pharmacokinetic study in subjects with hepatic cirrhosis (Child-Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50&nbsp;%, 57&nbsp;% and 59&nbsp;%), relative to matched healthy controls. (see section 4.2)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">In a pharmacokinetic study in 99 subjects aged 1 month to &lt;16 years receiving brivaracetam oral solution, plasma concentrations were shown to be dose-proportional in all age groups. Population pharmacokinetics modeling indicated that the dose of 2.0&nbsp;mg/kg twice a day provides the same steady-state average plasma concentration as in adults receiving 100&nbsp;mg twice daily.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Body weight</em></p><p dir="ltr">A 40&nbsp;% decrease in steady-state plasma concentration has been estimated across a body weight range from 46&nbsp;kg to 115&nbsp;kg. However, this is not considered to be a clinically relevant difference.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Gender</em></p><p dir="ltr">There are no<strong><em> </em></strong>clinically relevant<strong><em> </em></strong>differences in the pharmacokinetics of brivaracetam by gender.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Race</em></p><p dir="ltr">The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, Asian) in a population pharmacokinetic modeling from epilepsy patients. The number of patients with other ethnic background was limited.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacokinetic/pharmacodynamics relationship</u></p><p dir="ltr">The EC50 (brivaracetam plasma concentration corresponding to 50&nbsp;% of the maximum effect) was estimated to be 0.57&nbsp;mg/L. This plasma concentration is slightly above the median exposure obtained after brivaracetam doses of 50&nbsp;mg/day. Further seizure frequency reduction is obtained by increasing the dose to 100&nbsp;mg/day and reaches a plateau at 200&nbsp;mg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In safety pharmacology studies, the predominant effects were CNS related (mainly transient CNS depression and decreased spontaneous locomotor activity) seen at multiples (greater than 50 fold) of the pharmacologically active dose of brivaracetam, 2&nbsp;mg/kg. Learning and memory function were not affected.</p><p dir="ltr">Findings not observed in clinical studies, but seen in the repeated-dose toxicology dog studies at exposure similar to the clinical plasma AUC, were hepatotoxic effects (mainly porphyria). However, toxicological data accumulated on brivaracetam and on a structurally-related compound indicate that the dog liver changes have developed through mechanisms not relevant for humans. No adverse liver changes were seen in rats and monkeys following chronic administration of brivaracetam at 5- and 42-fold the clinical AUC exposure. In monkeys, CNS signs (prostrate, loss of balance, clumsy movements) occurred at 64 fold the clinical C<sub>max</sub>, these effects being less apparent over time.</p><p dir="ltr">Genotoxicity studies have not detected any mutagenic or clastogenic activity. Carcinogenicity studies did not indicate any oncogenic potential in rats, whereas increased incidences of hepatocellular tumors in male mice are considered to result of a non-genotoxic, mode of action linked to a phenobarbitone-like liver enzyme induction, which is a known rodent specific phenomenon.</p><p dir="ltr">Brivaracetam did not affect male or female fertility and has demonstrated no teratogenic potential in either rat or rabbit. Embryotoxicity was observed in rabbits at a maternal toxic dose of brivaracetam with an exposure level 8-fold the clinical AUC exposure at the maximum recommended dose. In rats, brivaracetam was shown to readily cross the placenta and to be excreted in milk of lactating rats with concentrations similar to maternal plasma levels.</p><p dir="ltr">Brivaracetam did not show any dependence potential in rats.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Juvenile animals studies</u></p><p dir="ltr">In juvenile rats, brivaracetam exposure levels 6- to 15-fold the clinical AUC exposure at the maximum recommended dose induced developmental adverse effects (i.e. mortality, clinical signs, decreased body weight and lower brain weight). There were no adverse effects on CNS function, neuropathological and brain histopathological examination. In juvenile dogs, the brivaracetam-induced changes at the exposure level 6- fold the clinical AUC were similar to those observed in adult animals. There were no adverse effects in any of the standard developmental or maturation endpoints.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Core</u></p><p dir="ltr">Croscarmellose Sodium,</p><p dir="ltr">Lactose monohydrate</p><p dir="ltr">Betadex</p><p dir="ltr">Lactose anhydrous</p><p dir="ltr">Magnesium stearate</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Coating</u></p><p dir="ltr"><u>Briviact 10&nbsp;mg film-coated tablets</u></p><p dir="ltr">Polyvinyl alcohol</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Macrogol 3350</p><p dir="ltr">Talc.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 25&nbsp;mg film-coated tablets</u></p><p dir="ltr">Polyvinyl alcohol</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Macrogol 3350</p><p dir="ltr">Talc</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">Iron oxide black (E172).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 50&nbsp;mg film-coated tablets</u></p><p dir="ltr">Polyvinyl alcohol</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Macrogol 3350</p><p dir="ltr">Talc</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">Iron oxide red (E172).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 75&nbsp;mg film-coated tablets</u></p><p dir="ltr">Polyvinyl alcohol</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Macrogol 3350</p><p dir="ltr">Talc</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">Iron oxide red (E172)</p><p dir="ltr">Iron oxide black (E172).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 100&nbsp;mg film-coated tablets</u></p><p dir="ltr">Polyvinyl alcohol</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Macrogol 3350</p><p dir="ltr">Talc</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">Iron oxide black (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Briviact 10&nbsp;mg film-coated tablets</u></p><ul dir="ltr"><li>Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters</li><li>Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 25&nbsp;mg film-coated tablets</u></p><ul dir="ltr"><li>Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters</li><li>Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 50&nbsp;mg film-coated tablets</u></p><ul dir="ltr"><li>Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters</li><li>Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 75&nbsp;mg film-coated tablets</u></p><ul dir="ltr"><li>Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters</li><li>Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Briviact 100&nbsp;mg film-coated tablets</u></p><ul dir="ltr"><li>Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) film-coated tablets in PVC/PCTFE - Aluminium blisters</li><li>Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p><p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21 April 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>